Novavax reported $1.67B in Current Liabilities for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Adma Biologics ADMA:US USD 44.44M 16.37M
Agenus AGEN:US USD 173.07M 13.35M
Astrazeneca AZN:US USD 24.85B 3.04B
AstraZeneca AZN:LN USD 24.85B 3.04B
Dynavax Technologies DVAX:US USD 244.08M 101.12M
Geron GERN:US USD 82.81M 35.93M
GlaxoSmithKline GSK:LN GBP 22.81B 1.86B
Mannkind MNKD:US USD 59.6M 33K
Minerva Neurosciences NERV:US USD 2.2M 1.21M
Moderna Inc MRNA:US USD 6.81B 5M
Novartis NVS:US USD 28.66B 496M
Novavax NVAX:US USD 1.67B 488.28M
Pain Therapeutics PTIE:US USD 8.31M 414K
Peregrine Pharmaceuticals PPHM:US USD 82.38M 10.97M
Sarepta Therapeutics SRPT:US USD 602.92M 57.35M
Tg Therapeutics TGTX:US USD 36.45M 6.88M